Adverse outcome pathways - development and potential regulatory application

被引:1
|
作者
Rossi Lima, Thania Rios [1 ]
de Souza, Nathalia Pereira [1 ]
Pereira, Lilian Cristina [1 ,2 ]
Viana de Camargo, Joao Lauro [1 ]
机构
[1] Univ Estadual Paulista, Ctr Evaluat Environm Impact Human Hlth TOXICAM, Dept Pathol, Botucatu, SP, Brazil
[2] Univ Estadual Paulista, Sch Agr Sci, Dept Bioproc & Biotechnol, Botucatu, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Adverse Outcome Pathways; Hazard Assessment; Mode of Action; Risk Assessment; Regulatory Toxicology; BRADFORD-HILL CONSIDERATIONS; URINARY-BLADDER CARCINOGENS; CONCEPTUAL-FRAMEWORK; SCIENTIFIC CONFIDENCE; 21ST-CENTURY ROADMAP; IPCS FRAMEWORK; MODE; TOXICITY; SUPPORT; RELEVANCE;
D O I
10.22239/2317-269x.01835
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Over the last two decades, chemical safety assessment and regulatory toxicology have progressed from empirical science based on direct observation of apical adverse outcomes in whole organisms to a predictive practice that infers outcomes and risks on the basis of accumulated understanding of toxicological mechanisms and modes of action. Objective: To provide general concepts on how Adverse Outcome Pathways (AOPs) are developed and examples related to skin sensitization, endocrine disruption, and mitochondrial dysfunction. Method: Narrative review based on data of the scientific literature relevant to the theme addressed and on the experience of the authors. Results: An AOP framework provides a systematic approach to organize knowledge about mechanisms of toxicity that may inform analytical domains in regulatory decision-making. AOPs are open structures that may indicate not only data gaps in the understanding of a toxicity process, but also testing procedures that will generate the necessary knowledge to fill those gaps. Every AOP should be continuously refined through the collaborative efforts of the scientific community. Depending on the amount and detail of information that is successively inserted, AOP may progress from the stage of a putative AOP to the stages of qualitative and quantitative AOPs, which are more fit-for-purpose to support regulatory decision-making. Conclusions: Continuous collaboration between AOP developers within the scientific community and the regulatory corps toward the development of this mechanistic structure will support the advancement of toxicological sciences, regardless of its immediate application for regulatory purposes.
引用
收藏
页码:2 / 13
页数:12
相关论文
共 50 条
  • [31] Development and application of an adverse outcome pathway of cholestatic liver injury
    Vinken, M.
    TOXICOLOGY LETTERS, 2021, 350 : S38 - S39
  • [32] Pathways of Number Line Development in Children Predictors and Risk for Adverse Mathematical Outcome
    Friso-van den Bos, Ilona
    Van Luit, Johannes E. H.
    Kroesbergen, Evelyn H.
    Xenidou-Dervou, Iro
    Van Lieshout, Ernest C. D. M.
    Van der Schoot, Menno
    Jonkman, Lisa M.
    ZEITSCHRIFT FUR PSYCHOLOGIE-JOURNAL OF PSYCHOLOGY, 2015, 223 (02): : 120 - 128
  • [33] Applying Evidence-Based Methods to the Development and Use of Adverse Outcome Pathways
    de Vries, Rob B. M.
    Angrish, Michelle
    Browne, Patience
    Brozek, Jan
    Rooney, Andrew A.
    Wikoff, Daniele S.
    Whaley, Paul
    Edwards, Stephen W.
    Morgan, Rebecca L.
    Druwe, Ingrid L.
    Hoffmann, Sebastian
    Hartung, Thomas
    Thayer, Kristina
    Avey, Marc T.
    Beverly, Brandiese E. J.
    Falavigna, Maicon
    Gibbons, Catherine
    Goyak, Katy
    Kraft, Andrew
    Nampo, Fernando
    Qaseem, Amir
    Sears, Meg
    Singh, Jasvinder A.
    Willett, Catherine
    Yost, Erin Y.
    Schunemann, Holger
    Tsaioun, Katya
    ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2021, 38 (02) : 336 - 347
  • [34] The development of adverse outcome pathways for mutagenic effects for the organization for economic co-operation and development
    Yauk, Carole L.
    Bishop, Jack
    Dearfield, Kerry L.
    Douglas, George R.
    Hales, Barbara F.
    Luijten, Mirjam
    O'Brien, Jason M.
    Robaire, Bernard
    Sram, Radim
    van Benthem, Jan
    Wade, Mike G.
    White, Paul A.
    Marchetti, Francesco
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2013, 54 (02) : 79 - 81
  • [35] Application of Adverse Outcome Pathways to US EPA's Endocrine Disruptor Screening Program
    Browne, Patience
    Noyes, Pamela D.
    Casey, Warren M.
    Dix, David J.
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2017, 125 (09)
  • [36] Application of benchmark dose modeling to protein expression data in the development and analysis of mode of action/adverse outcome pathways for testicular toxicity
    Chepelev, Nikolai L.
    Meek, M. E.
    Yauk, Carole Lyn
    JOURNAL OF APPLIED TOXICOLOGY, 2014, 34 (11) : 1115 - 1121
  • [37] Creating Quantitative Adverse Outcome Pathways with Effectopedia
    Aladjov, H. T.
    TOXICOLOGY LETTERS, 2018, 295 : S11 - S11
  • [38] Adverse Outcome Pathways and the Paradox of Complex Simplicity
    Knapen, Dries
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2021, 40 (11) : 2950 - 2952
  • [39] Skin Sensitisation, Adverse Outcome Pathways and Alternatives
    Basketter, David
    ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2016, 44 (05): : 431 - 436
  • [40] Why Adverse Outcome Pathways Need to be FAIR
    Wittwehr, Clemens
    Clerbaux, Laure-Alix
    Edwards, Stephen
    Angrish, Michelle
    Mortensen, Holly
    Carusi, Annamaria
    Gromelski, Maciej
    Lekka, Eftychia
    Virvilis, Vassilis
    Martens, Marvin
    Santos, Luiz Olavo Bonino da Silva
    Nymark, Penny
    ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2024, 41 (01) : 50 - 56